Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Peter Kozuch"'
Autor:
Noam Harpaz, Samarth Hegde, Lisa Fitzgerald, Stephen Ward, Miriam Merad, Thomas Marron, Zheng Zhu, Qingqing Liu, Celina Ang, Deborah Doroshow, Umut Sarpel, Kathy Wu, Ana Acuna-Villaorduna, Natalie Lucas, Nicholas Venturini, Raphaël Mattiuz, Clotilde Hennequin, Jessica Le Berichel, Theodore Chin, Amanda Reid, Leanna Troncoso, David Greenwald, Ari Grinspan, Steve Itzkowitz, Aimee L Lucas, Dana Zalkin, Peter Kozuch, Sergey Khaitov, Alex Ky-Miyasaka, Randolph Steinhagen, Patricia Sylla, Gunther Kretschmar, John Paulsen, Xintong Wang, Alexandros D Polydorides, Deirdre Cohen, Gabriela Fazilov, Gary Shelton, Amber Cameron, Megan Yuan
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/f4976598fe474b3bbabfbc038fa62732
Autor:
Linda Wu, Celina Ang, Sofya Pintova, Max W. Sung, Peter Kozuch, Sirish Dharmapuri, Noah A Cohen, Myron E. Schwartz, John P. Mandeli, Deepak Saxena, Deirdre Jill Cohen
Publikováno v:
Journal of Clinical Oncology. 41:TPS759-TPS759
TPS759 Background: Neoadjuvant therapy is now a standard strategy for localized PDAC, and this preoperative window provides an excellent opportunity in which to test novel therapeutic approaches. Trials using IO in PDAC have largely been unsuccessful
Autor:
Sirish Dharmapuri, Rafael Cabal, Giorgio Ioannou, Sinem Ozbey, John Paulsen, Celina Ang, Umut Sarpel, Max W. Sung, Peter Kozuch, Myron E. Schwartz, Deirdre Jill Cohen, Sacha Gnjatic, Sofya Pintova
Publikováno v:
Journal of Clinical Oncology. 40:e16151-e16151
e16151 Background: NACT is increasingly being used in the management of locally advanced BTC. Emerging evidence suggests a potential key contributing role of tumor infiltrating immune cells in the prognosis & response to therapy. We set out to charac
Autor:
Emilia Bagiella, Jenny L. Lin, Rolfe Morrison, Dena Schulman-Green, Peter Kozuch, Jason Gonsky, Nina A. Bickell, Sofya Pintova, Cardinale B. Smith, Natalia Egorova
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b8deb310806906ddbacc174cd18bfa5
https://doi.org/10.25302/07.2020.ihs.131006444
https://doi.org/10.25302/07.2020.ihs.131006444
Autor:
Sofya Pintova, Emilia Bagiella, Nina A. Bickell, Jenny J. Lin, Natalia N. Egorova, Kerin B. Adelson, Peter Kozuch, Cardinale B. Smith, Anthony L. Back, Jason Gonsky
Publikováno v:
JCO oncology practice. 16(9)
PURPOSE: Patients with advanced cancer often have a poor understanding of cancer incurability, which correlates with more aggressive treatment near the end of life (EOL). We sought to determine whether training oncologists to elicit patient values fo
Publikováno v:
CardioVascular and Interventional Radiology. 38:1645-1648
Prophylactic gastroduodenal artery (GDA) and right gastric artery (RGA) embolization for prevention of gastric ulceration in patients with hepatic metastases from colorectal cancer undergoing Selective Internal Radiation Therapy (SIRT) are relatively
Publikováno v:
Investigational new drugs. 35(6)
Background Metformin has been shown to have anti-neoplastic activity in non-small cell lung cancer (NSCLC) in both preclinical and observational studies, however this has never been prospectively evaluated. This single-arm phase II trial, while not f
Autor:
Peter Kozuch, Kevin M. Sullivan
Publikováno v:
The Cancer Journal. 18:633-641
Metastatic pancreatic cancer is a devastating disease with a dismal prognosis. Gemcitabine chemotherapy has been the mainstay of treatment for many years. Efforts to improve survival outcomes with gemcitabine-based combination chemotherapy regimens h
Publikováno v:
Chemotherapy Research and Practice
Patients with metastatic colorectal cancer have a poor prognosis and present a challenge to clinicians. The role of the antiepidermal growth factor receptor (EGFR) pathway in tumorogenesis and tumor progression has been well defined. This paper will
Autor:
Tina Ashley Khair, Peter Kozuch
Publikováno v:
Seminars in Colon and Rectal Surgery. 21:120-125
A decades long challenge for clinicians caring for patients with adenocarcinoma of the rectum has been to optimize oncologic outcomes while minimizing both disease- and treatment-associated morbidities. This review summarizes the landmark trials that